Free Trial

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics logo
$1.80 +0.09 (+4.97%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MacroGenics Stock (NASDAQ:MGNX)

Advanced

Key Stats

Today's Range
$1.72
$1.83
50-Day Range
$1.44
$2.00
52-Week Range
$0.99
$5.10
Volume
327,692 shs
Average Volume
900,614 shs
Market Capitalization
$113.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.60
Consensus Rating
Moderate Buy

Company Overview

MacroGenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

MGNX MarketRank™: 

MacroGenics scored higher than 90% of companies evaluated by MarketBeat, and ranked 104th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Upside Potential

    MacroGenics has a consensus price target of $3.60, representing about 106.9% upside from its current price of $1.74.

  • Amount of Analyst Coverage

    MacroGenics has only been the subject of 2 research reports in the past 90 days.

  • Read more about MacroGenics' stock forecast and price target.
  • Earnings Growth

    Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MacroGenics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MacroGenics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MacroGenics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MacroGenics' valuation and earnings.
  • Percentage of Shares Shorted

    6.42% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 0.80%, indicating that investor sentiment is improving.
  • Dividend Yield

    MacroGenics does not currently pay a dividend.

  • Dividend Growth

    MacroGenics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.42% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 0.80%, indicating that investor sentiment is improving.
  • News Sentiment

    MacroGenics has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for MacroGenics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for MGNX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,515.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MacroGenics' insider trading history.
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MGNX Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
William Heiden Bought 909% More Shares In MacroGenics
William Heiden Bought 909% More Shares In MacroGenics
Stifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)
Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)
See More Headlines

MGNX Stock Analysis - Frequently Asked Questions

MacroGenics' stock was trading at $3.25 on January 1st, 2025. Since then, MGNX shares have decreased by 46.5% and is now trading at $1.74.

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company had revenue of $22.24 million for the quarter, compared to analyst estimates of $28.06 million. MacroGenics had a negative trailing twelve-month return on equity of 40.24% and a negative net margin of 21.99%.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
8/14/2025
Today
10/03/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGNX
CIK
1125345
Employees
430
Year Founded
2000

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.00
Potential Upside/Downside
+106.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$66.97 million
Net Margins
-21.99%
Pretax Margin
-21.36%
Return on Equity
-40.24%
Return on Assets
-14.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.26
Quick Ratio
5.02

Sales & Book Value

Annual Sales
$163.87 million
Price / Sales
0.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
63,206,000
Free Float
54,989,000
Market Cap
$109.98 million
Optionable
Optionable
Beta
1.61

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:MGNX) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners